GlassScriptPhysician profile
Tiffany L Adams
NPI 1427556125
$2,386.02
in general payments reported to CMS, 2019-2025
21 companies · $950 in 2025
The $950 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $79.09 · 2023: $709 · 2024: $648 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.40 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.07 | 2022-2025 | Dalvance, Teflaro, Avycaz |
| Paratek Pharmaceuticals, INC. | $300.97 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $250.86 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Melinta Therapeutics, LLC | $229.16 | 2022-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Shionogi INC | $227.72 | 2024-2025 | Fetroja |
| Insmed, INC. | $161.71 | 2023-2025 | Arikayce |
| Astellas Pharma US INC | $143.47 | 2023-2024 | Cresemba |
| Gilead Sciences, INC. | $122.60 | 2023-2024 | Veklury |
| Aimmune Therapeutics, INC. | $109.96 | 2023-2025 | Vowst |
| Xeris Pharmaceuticals, INC. | $74.64 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $54.03 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.66 | 2024-2025 | Jardiance |
| Cequr Corporation | $22.87 | 2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $20.10 | 2025 | |
| Lilly USA, LLC | $18.23 | 2025 | Zepbound, Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $17.54 | 2025 | Heplisav-B |
| Amgen INC. | $16.88 | 2023 | Prolia, Evenity |
| Beta Bionics, INC. | $15.54 | 2024 | Ilet Bionic Pancreas |
| Blue Surgical LLC | $15.42 | 2025 | |
| Medtronic, INC. | $15.11 | 2025 | Minimed 780g |
| Ferring Pharmaceuticals INC. | $13.48 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.